Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SRZN
Upturn stock ratingUpturn stock rating

Surrozen Inc (SRZN)

Upturn stock ratingUpturn stock rating
$8.94
Last Close (24-hour delay)
Profit since last BUY-10.51%
upturn advisory
WEAK BUY
BUY since 7 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SRZN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $37

1 Year Target Price $37

Analysts Price Target For last 52 week
$37Target price
Low$5.9
Current$8.94
high$18.17

Analysis of Past Performance

Type Stock
Historic Profit -74.62%
Avg. Invested days 19
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 77.23M USD
Price to earnings Ratio -
1Y Target Price 37
Price to earnings Ratio -
1Y Target Price 37
Volume (30-day avg) 2
Beta 0.57
52 Weeks Range 5.90 - 18.17
Updated Date 06/30/2025
52 Weeks Range 5.90 - 18.17
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -24.86

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -971.62%

Management Effectiveness

Return on Assets (TTM) -21.41%
Return on Equity (TTM) -456.32%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -16630013
Price to Sales(TTM) 6.64
Enterprise Value -16630013
Price to Sales(TTM) 6.64
Enterprise Value to Revenue 2.73
Enterprise Value to EBITDA 0.71
Shares Outstanding 8562580
Shares Floating 5400593
Shares Outstanding 8562580
Shares Floating 5400593
Percent Insiders 4.09
Percent Institutions 64.55

Analyst Ratings

Rating 2
Target Price 37
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Surrozen Inc

stock logo

Company Overview

overview logo History and Background

Surrozen Inc. was a biotechnology company focused on discovering and developing novel regenerative medicines to treat diseases with significant unmet medical needs. Founded in 2016, it aimed to repair and regenerate damaged tissues and organs. The company ceased operations in January 2024.

business area logo Core Business Areas

  • Regenerative Medicine Development: Focused on discovering and developing novel regenerative medicines targeting the Wnt pathway.

leadership logo Leadership and Structure

Surrozen Inc. had a leadership team comprised of experienced biotechnology executives and scientists. Details on the organizational structure are no longer relevant due to the company's closure.

Top Products and Market Share

overview logo Key Offerings

  • SZN-1326: A clinical-stage antibody designed to activate Wnt signaling for the treatment of severe alcoholic hepatitis (sAH) and other liver diseases. The company ceased operations before any significant revenue generation or market share establishment. Key competitors include companies developing other sAH treatments, such as Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT). Intercept was acquired by Alfasigma in December 2023.
  • SZN-043: A preclinical asset targeting the Wnt pathway for potential treatment of inflammatory bowel disease (IBD). It did not generate revenue, and no market share data exists. Competitors include companies working on IBD therapies like AbbVie (ABBV) and Takeda (TAK).

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine industry is focused on developing therapies that repair or replace damaged tissues and organs. It is a high-risk, high-reward industry with significant unmet medical needs and potential for growth.

Positioning

Surrozen aimed to position itself as a leader in Wnt pathway-targeted regenerative medicine. However, it was in the early stages of development and did not achieve significant market penetration before its closure.

Total Addressable Market (TAM)

The total addressable market for regenerative medicine is estimated to be billions of dollars, with significant potential for growth in various indications. Surrozen aimed to capture a portion of this TAM through its Wnt-targeted therapies, but the company shutdown before achieving market capture.

Upturn SWOT Analysis

Strengths

  • Novel Wnt pathway-targeted approach
  • Experienced leadership team (at time of operation)
  • Promising preclinical and early clinical data (at time of operation)

Weaknesses

  • High cash burn rate
  • Dependence on financing
  • Early stage of development
  • Clinical trial risk
  • Company closed operations

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Positive clinical trial results

Threats

  • Clinical trial failures
  • Competition from established therapies
  • Regulatory hurdles
  • Difficulty in raising capital

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • ABBV

Competitive Landscape

Surrozen faced intense competition from established pharmaceutical companies with significantly more resources and approved products. Its competitive advantage relied on its novel Wnt pathway approach, but it was unable to overcome financial challenges and bring its therapies to market.

Growth Trajectory and Initiatives

Historical Growth: Surrozen's historical growth was limited as it was focused on research and development. The company ceased operations before achieving significant revenue generation.

Future Projections: Future projections are nonexistent due to company closure.

Recent Initiatives: Recent initiatives are irrelevant due to company closure.

Summary

Surrozen Inc. was a biotechnology company focused on regenerative medicine that ultimately ceased operations due to financial constraints. Its novel Wnt pathway approach showed promise, but the company was unable to secure sufficient funding to advance its pipeline. The closure resulted in significant losses for shareholders. The high cash burn rate and early stage of development proved unsustainable. Surrozen's fate underscores the risks inherent in early-stage biotech investments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (now historical)
  • Press Releases (now historical)
  • Industry Reports
  • Company Website (now defunct)

Disclaimers:

This analysis is based on publicly available information and historical data. The company has ceased operations, rendering much of the data irrelevant for current investment decisions. This analysis should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Surrozen Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2021-01-11
CEO, President & Director Mr. Craig C. Parker M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 40
Full time employees 40

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.